Quoin Pharmaceuticals Ltd
QNRX13.750USD
-0.450-3.17%
收盘 12/22, 16:00（美东）报价延迟15分钟
283.06M总市值
亏损市盈率 TTM
关于 Quoin Pharmaceuticals Ltd 公司
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Quoin Pharmaceuticals Ltd简介
公司代码QNRX
公司名称Quoin Pharmaceuticals Ltd
上市日期Nov 01, 1989
CEOMyers (Michael)
员工数量3
证券类型Depository Receipt
年结日Nov 01
公司地址23 Hata'as Street
城市KFAR SABA
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Israel
邮编44425
电话97299741444
网址https://quoinpharma.com/
公司代码QNRX
上市日期Nov 01, 1989
CEOMyers (Michael)
Quoin Pharmaceuticals Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
440.00
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Mr. Yali Sheffi
Mr. Yali Sheffi
Independent External Director
Independent External Director
--
--
Mr. Guy Sapir
Mr. Guy Sapir
Internal Auditor
Internal Auditor
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Ms. Sally Lawlor
Ms. Sally Lawlor
Chief Financial Officer
Chief Financial Officer
440.00
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 12月19日 周五
更新时间: 12月19日 周五
持股股东
股东类型
持股股东
持股股东
占比
Ikarian Capital LLC
25.21%
Stonepine Capital Management, LLC
7.00%
Resolute Capital Asset Partners LLC
5.96%
Myers (Michael)
2.05%
Carter (Denise P)
2.05%
其他
57.72%
持股股东
持股股东
占比
Ikarian Capital LLC
25.21%
Stonepine Capital Management, LLC
7.00%
Resolute Capital Asset Partners LLC
5.96%
Myers (Michael)
2.05%
Carter (Denise P)
2.05%
其他
57.72%
股东类型
持股股东
占比
Hedge Fund
25.21%
Investment Advisor/Hedge Fund
7.03%
Individual Investor
6.82%
Investment Advisor
6.10%
其他
54.83%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
28
2.54K
0.30%
-52.73K
2025Q2
34
51.05K
8.68%
-35.06K
2025Q1
35
78.22K
9.34%
-7.90K
2024Q4
33
2.93M
35.77%
+2.56M
2024Q3
29
288.95K
5.54%
-93.09K
2024Q2
30
301.96K
12.37%
-13.30K
2024Q1
28
276.13K
11.96%
+132.88K
2023Q4
28
104.03K
10.54%
-33.36K
2023Q3
27
83.72K
8.48%
+6.49K
2023Q2
28
91.62K
18.66%
+37.20K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Ikarian Capital LLC
--
0%
-7.86K
-100.00%
Mar 31, 2025
Myers (Michael)
17.22K
0.08%
--
--
Jul 16, 2025
Carter (Denise P)
17.22K
0.08%
-1.00
-0.01%
Jul 16, 2025
Langer (Dennis H)
1.00
0%
-1.00
-50.00%
Jul 16, 2025
Dunn (Gordon)
4.32K
0.02%
--
--
Jul 16, 2025
Culverwell (Anthony James)
2.87K
0.01%
--
--
Jul 16, 2025
Rhumbline Advisers Ltd. Partnership
1.24K
0.01%
+49.00
+4.11%
Jun 30, 2025
Lawlor (Sally Bridget)
440.00
0%
+440.00
--
Aug 18, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Mar 26, 2025
Merger
35→1
Mar 26, 2025
Merger
20→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
公告日期
类型
比率
Mar 26, 2025
Merger
35→1
Mar 26, 2025
Merger
20→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jun 28, 2023
Merger
12→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
Jul 29, 2022
Merger
12.5→1
查看更多
常见问题
Quoin Pharmaceuticals Ltd的前五大股东是谁？
Quoin Pharmaceuticals Ltd 的前五大股东如下：
Ikarian Capital LLC持有股份：0.00，占总股份比例：0.00%。
Myers (Michael)持有股份：17.22K，占总股份比例：0.08%。
Carter (Denise P)持有股份：17.22K，占总股份比例：0.08%。
Langer (Dennis H)持有股份：1.00，占总股份比例：0.00%。
Dunn (Gordon)持有股份：4.32K，占总股份比例：0.02%。
Ikarian Capital LLC持有股份：0.00，占总股份比例：0.00%。
Myers (Michael)持有股份：17.22K，占总股份比例：0.08%。
Carter (Denise P)持有股份：17.22K，占总股份比例：0.08%。
Langer (Dennis H)持有股份：1.00，占总股份比例：0.00%。
Dunn (Gordon)持有股份：4.32K，占总股份比例：0.02%。
Quoin Pharmaceuticals Ltd的前三大股东类型是什么？
Quoin Pharmaceuticals Ltd 的前三大股东类型分别是：
Ikarian Capital LLC
Stonepine Capital Management, LLC
Resolute Capital Asset Partners LLC
Ikarian Capital LLC
Stonepine Capital Management, LLC
Resolute Capital Asset Partners LLC
有多少机构持有Quoin Pharmaceuticals Ltd(QNRX)的股份？
截至2025Q3，共有28家机构持有Quoin Pharmaceuticals Ltd的股份，合计持有的股份价值约为2.54K，占公司总股份的0.30%。与2025Q2相比，机构持股有所增加，增幅为-8.38%。
哪个业务部门对Quoin Pharmaceuticals Ltd的收入贡献最大？
在--，--业务部门对Quoin Pharmaceuticals Ltd的收入贡献最大，创收--，占总收入的--%。
